Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 16;4(4):311-317.
doi: 10.1016/j.jncc.2024.08.001. eCollection 2024 Dec.

Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study

Affiliations

Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study

Xun Tian et al. J Natl Cancer Cent. .

Abstract

Objective: We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test.

Methods: 4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up.

Results: At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (P < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%-95.4%] vs. 75.5% [71.2%-79.8%], P < 0.001) and higher positive predictive value (36.4% [22.1%-50.6%] vs. 15.2% [8.5%-21.8%], P < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], P < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%).

Conclusion: As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients.

Keywords: Cervical cancer screening; Cervical intraepithelial neoplasia; Colposcopy; HPV integration; Human papillomavirus.

PubMed Disclaimer

Conflict of interest statement

Ding Ma and Zheng Hu are inventors of a patent (ZL201510217845.0) for the HPV integration test. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig 1
Fig. 1
Study population enrollment flow diagram. Abbreviations: HPV, human papillomavirus; TCT, Thinprep cytologic test; CIN, cervical intraepithelial neoplasia.
Fig 2
Fig. 2
The immediate risk of CIN3+ for women stratified by HPV integration and cytology in HPV-positive women. The risks of CIN3+ are plotted on the y-axis, with the number and percentage of women indicated. The dotted line corresponds to the colposcopy referral threshold (4%). The dashed line corresponds to the expedited treatment or colposcopy acceptable threshold (25%). The dash-dotted line corresponds to the expedited treatment preferred threshold (60%). Abbreviations: ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignant neoplasm.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
    1. WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention (Second edition): WHO Guidelines. 2021 https://www.who.int/publications/i/item/9789240030824 Accessed April 20, 2024.
    1. Molina MA, Steenbergen RDM, Pumpe A, et al. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends Mol Med. 2024;30(9):890–902. - PubMed
    1. Pandhi D, Sonthalia S. Human papilloma virus vaccines: current scenario. Indian J Sex Transm Dis AIDS. 2011;32(2):75–85. - PMC - PubMed
    1. Traynor D, Martin CM, White C, et al. Raman spectroscopy of liquid-based cervical smear samples as a triage to stratify women who are HPV-positive on screening. Cancers (Basel) 2021;13(9):2008. - PMC - PubMed

LinkOut - more resources